Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allergy Therapeutics, a specialty pharmaceutical company, has submitted its complete response to the Paul Ehrlich Institute (PEI) on its Marketing Authorization Application (MAA) for Pollinex Quattro Complete Grass in Germany.
Subscribe to our email newsletter
Pollinex Quattro Complete (MATA MPL) is a four injection therapeutic vaccine, used to treat allergic conditions which provides relief in three weeks after treatment.
The company has also submitted a study protocol to the US FDA to enable the formal lifting of the clinical hold, enabling the progress of MATA MPL development programmes in the US.
Allergy Therapeutics Chief Executive Manuel Llobet said the move is a major step in the regulatory activities in Germany and the US.
"With our initiatives in Latin America, Allergy Therapeutics is now active on three continents, and we are making good progress towards achieving our ambition to be one of the top three companies in the global allergy immunotherapy field," Llobet added.